NOV 18, 2020 6:30 AM PST

Nerve Damage as a Prognostic Marker for Rare Autoimmune Disease

WRITTEN BY: Tara Fernandez

Researchers have identified a new prognostic biomarker for Guillain-Barré syndrome (GBS), a rare autoimmune disorder that attacks the nerves and can eventually paralyze the entire body. The biomarker, neurofilament light chain, or NfL, signals the presence of axonal damage. As published in the Journal of Neurology, Neurosurgery, and Psychiatry, high circulating levels of NfL in GBS patients were found to be associated with more severe disabilities.

These findings significantly impact the clinical strategies for managing GBS and increase neurologists' understanding of the physiological processes underlying this devastating disease.

"First, they confirm that residual long-term disability in GBS is clearly associated to the degree of axonal damage that happens at the onset of the disease," said Luis Querol, senior author of the study.

"They also suggest that serum NfL could be used to stratify patients at admission, and in the future, select patients who may be candidates for more aggressive therapies or those who may have good prognosis independently of the apparent severity they have at onset," said Querol.

The root causes of GBS continue to mystify scientists, although a large proportion of patients report having a severe respiratory or gastrointestinal infection in the leadup to the disease. Among the early signs of GBS are a prickling sensation in the fingers, limb weakness, and double vision.

Measuring the degeneration of axons, or nerve fibers, can determine a GBS patient’s outcomes and shape clinical interventions moving forward, said Bart Jacobs from the Erasmus Medical Center in Rotterdam. 

In an editorial on the study, Jacobs writes: "Axonal injury may occur in AMAN as well as acute inflammatory demyelinating polyneuropathy and in severe cases may result in irreversible degeneration. Treatment with immunoglobulins or plasma-exchange aims to prevent further axonal injury, but clinicians currently have no methods to monitor the response directly."

 

 

Sources: MedPage Today, Journal of Neurology, Neurosurgery & Psychiatry.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
NOV 12, 2020
Clinical & Molecular DX
Study Shows 1 in 5 COVID Tests Are False Positives
NOV 12, 2020
Study Shows 1 in 5 COVID Tests Are False Positives
  A study published in The BMJ has brought to light that the rapid finger-prick COVID-19 test may not be quite as r ...
DEC 08, 2020
Clinical & Molecular DX
"Honey, I Shrunk the PCR."
DEC 08, 2020
"Honey, I Shrunk the PCR."
In the 1530s, hundreds of years before microscopes and Petri dishes, an Italian physician called Girolamo Fracastoro wro ...
JAN 14, 2021
Clinical & Molecular DX
Tip of the Iceberg: Inaccuracies in Prostate Cancer Diagnostics
JAN 14, 2021
Tip of the Iceberg: Inaccuracies in Prostate Cancer Diagnostics
  Only 10 percent of icebergs are visible on the surface of the water; the remaining 90 percent remains submerged. ...
FEB 11, 2021
Clinical & Molecular DX
Seeing if Hormone Therapy Will Work for Breast Cancer Patients
FEB 11, 2021
Seeing if Hormone Therapy Will Work for Breast Cancer Patients
Only around half of women diagnosed with breast cancer will benefit from hormonal therapy, a cancer treatment that adds, ...
FEB 16, 2021
Genetics & Genomics
Genetic Tests That Look for Rare, Disease-Causing Variants are Usually Wrong
FEB 16, 2021
Genetic Tests That Look for Rare, Disease-Causing Variants are Usually Wrong
While people carry mostly the same genes, there are small differences in the sequences of those genes that can have prof ...
FEB 25, 2021
Clinical & Molecular DX
Pure Gold: Mini Device Makes 3D Skin Maps
FEB 25, 2021
Pure Gold: Mini Device Makes 3D Skin Maps
Beauty is skin deep and so are wounds. Closely monitoring wound healing progress has been a challenge for doctors, mainl ...
Loading Comments...